Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ADL5859

Known as: ADL 5859, ADL-5859 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
  • V. Spahn, C. Stein
  • Expert opinion on investigational drugs
  • 2017
  • Corpus ID: 22258505
ABSTRACT Introduction: Opioids are widely used to treat severe pain. Most clinically used opioids activate µ-opioid receptors… Expand
2016
2016
Kappa opioid (KOP) receptor antagonists and delta opioid (DOP) receptor agonists have antidepressant-like effects in animal tests… Expand
2015
2015
The delta opioid receptor (DOR) has raised much interest for the development of new therapeutic drugs, particularly to treat… Expand
  • figure 1
  • figure 3
  • figure 4
2014
2014
Activation of δ opioid (DOP) receptors regulates pain and emotional responses, and also displays ligand‐biased agonism. KNT‐127… Expand
2013
2013
Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2012
2012
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de… Expand
Highly Cited
2009
Highly Cited
2009
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents… Expand
Highly Cited
2008
Highly Cited
2008
Selective delta opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain… Expand